Yumeng Mao

Nyckelord

  • cancer immune checkpoint
  • crispr-cas9
  • drug discovery
  • immune resistance
  • myeloid cells
  • pd1
  • pdl1

Biografi

Denna text finns inte på svenska, därför visas den engelska versionen.

Complete list of publications with citations on google scholar

https://scholar.google.com/citations?user=yx76OvsAAAAJ&hl=en

Forskning

Denna text finns inte på svenska, därför visas den engelska versionen.

Yumeng Mao is a Fellow at the Science for Life Laboratory and an associate senior lecturer at the Department of Immunology, Genetics and Pathology in Uppsala University. The research group aims to overcome resistance mechanisms against the PD-1/PD-L1 blockade therapy in cancer patients by elucidating the negative immune regulatory network using CRISPR/Cas9 precise genome editing (PGE) technology. The group has a special interest on rare cancer types where immunotherapy is less explored, e.g. childhood solid cancers. Prior to the appointment, Yumeng spent a few years at the Oncology R&D headquarter at AstraZeneca in Cambridge, United Kingdom, where he identified and led early drug discovery projects for novel cancer immunotherapy targets. He started his research career in cancer immunology in 2009 with Dr. Karl-Erik Hellström at the University of Washington (USA) and trained as a PhD candidate at the Karolinska Institute (Sweden) under the supervision of Prof. Rolf Kiessling. Yumeng was born and raised in Xi’an, China, where he obtained his undergraduate degree in Life Sciences.

Yumeng Mao

FÖLJ UPPSALA UNIVERSITET PÅ

facebook
instagram
youtube
linkedin